Moderate-to-heavy drinking reduced the effectiveness of anti-PD-1 cancer immunotherapy by roughly 50 percent in mice and was linked to poorer survival in patients, researchers from the University of North Carolina at Chapel Hill reported in Science Signaling on Nov. 17.
The study, led by Kristen N. Gilley of the Bowles Center for Alcohol Studies and Lineberger Comprehensive Cancer Center, combined mouse models of lung and bladder cancer with a retrospective review of patients treated at UNC Chapel Hill Cancer Hospital between 2014 and 2018.
Mechanism: Alcohol drives TIGIT up, T cells down
In mice given ethanol equivalent to three to six human drinks per day for five weeks before tumor implantation, anti-PD-1 therapy failed at nearly twice the rate seen in alcohol-free controls. Tumors in drinking mice showed fewer tumor-infiltrating CD4+ and CD8+ T cells, reduced interferon-gamma production, and a shift toward T-helper 17 phenotypes over T-helper 1 cells, the study found.
Critically, T cells in alcohol-exposed mice expressed higher levels of TIGIT, a second inhibitory receptor that acts as an additional brake on immune activity. “This work is an initial resource toward establishing the risk of regular alcohol use on the efficacy of [immune checkpoint inhibition] and identifying the mechanisms that might be targeted for intervention,” the authors wrote in the paper.
Human data: More than one drink a week tied to less benefit
Among lung cancer patients receiving anti-PD-1 therapy, those who self-reported regular alcohol use — defined in the clinical cohort as more than one drink per week — experienced reduced survival benefit compared with non-drinkers, Medical Xpress reported. News-Medical.net and EureKAlert! noted a separate threshold in the broader cohort of skin, lung, bladder, and head-and-neck cancer patients: eight or more drinks per week correlated with poorer survival after starting checkpoint inhibition.
Effects were less definitive in bladder cancer, melanoma, and head-and-neck cancer because alcohol-use reporting was too limited in those subgroups, the study authors said.
Dual blockade restores response in mice
Adding an anti-TIGIT antibody to anti-PD-1 treatment restored complete tumor response rates in alcohol-exposed mice to levels nearly matching those in non-drinking mice. Inhibiting SREBP-mediated lipid signaling with betulin also improved efficacy, though to a lesser extent than TIGIT blockade.
Clinical context: Most patients keep drinking
Despite standard oncologic advice to avoid alcohol, a prior study cited by the researchers found that 76.4 percent of cancer patients continued to drink. The authors argued that systematically recording alcohol consumption in cancer databases would clarify its impact across tumor types and therapies.
What this means for patients now
The study is preclinical and retrospective; it does not prove causation in humans, and the mouse dosing model represents moderate-to-heavy chronic use. No clinical guideline has yet changed based on these findings. Patients receiving or considering immune checkpoint inhibitors should discuss alcohol use with their oncology team.
Key numbers from alcohol immunotherapy study
| Measure | Finding | Source |
|---|---|---|
| Reduction in anti-PD-1 efficacy (mice) | ~50% | Gilley et al., Science Signaling |
| Clinical threshold linked to reduced survival (lung cohort) | >1 drink/week | Medical Xpress |
| Clinical threshold linked to reduced survival (mixed cohort) | ≥8 drinks/week | News-Medical.net / EureKAlert! |
| Cancer patients who continue drinking | 76.4% | Study citation (via all outlets) |
Study defines regular drinking thresholds
Does alcohol stop immunotherapy from working completely?
No. The study found a roughly 50 percent reduction in treatment efficacy in mice and an association with poorer survival in humans who drank regularly. Some benefit may remain, but the magnitude of reduction is clinically significant.
What counts as “regular” alcohol use in the human data?
Thresholds differed between cohorts. In the lung-cancer-specific analysis, more than one drink per week was associated with reduced benefit. In the broader mixed-cancer cohort, eight or more drinks per week correlated with worse survival.
Can the negative effect be reversed?
In mice, adding an anti-TIGIT antibody to standard anti-PD-1 therapy restored response rates nearly to the level of non-drinking mice. This combination has not yet been tested in alcohol-drinking cancer patients.
Chartered in 1789 and enrolling students by 1795, the University of North Carolina at Chapel Hill is one of the nation’s oldest public universities and the only one to confer degrees in the eighteenth century.
It anchors the Research Triangle alongside Duke and North Carolina State University and is classified as an R1 institution with very high research activity; the National Science Foundation ranked it ninth nationally for research and development expenditures in 2023 at $1.5 billion.
Should I stop drinking if I am on immunotherapy?
Oncologists already advise limiting or avoiding alcohol during cancer treatment. This study provides mechanistic evidence supporting that advice, but no formal guideline change has been announced. Discuss your specific situation with your care team.
Keep reading